Overall, we report that PTFs related to tumor focality/centricity, tumor location, hormone receptor and HER2 expression, cellular proliferation, as well as Oncotype DX® Breast Cancer Assay Recurrence Score® were significantly (P < 0.05) associated with performance for one or more cognitive function composite domains. The gene discussed is NR4A1; the disease is breast carcinoma.